MedPath

Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Completed
Conditions
Vulvovaginal Atrophy
Registration Number
NCT04607707
Lead Sponsor
Shionogi
Brief Summary

The primary objective of this study is to describe and assess participants' satisfaction with current vulvovaginal atrophy (VVA) treatment.

Detailed Description

This study is designed as a multicenter, cross-sectional, descriptive, observational study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
831
Inclusion Criteria
  • Women with natural menopause established for at least one year.
  • Absence of menstruation for at least one year.
  • Mild, moderate or severe VVA diagnosis.
  • Currently under treatment with either Ospemifene, Local Oestrogen Therapy or moisturizers for at least 3 months in accordance with the approved SmPC and/or Patient Leaflet
  • Patients providing writing informed consent for participating in the study.
Exclusion Criteria
  • Women who have never been previously treated for VVA
  • Women who have discontinued their VVA treatment due to a contraindication in the study group drug.
  • Patients using more than one VVA treatment at a time (except for lubricants).
  • Breastfeeding, pregnancy or under any kind of systemic hormonal treatment that causes amenorrhea.
  • Local phytotherapy for VVA.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Perception of Patient Satisfaction with Long-term VVA Treatment of Vulvovaginal Atrophy by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Perception of Patient Satisfaction with Their Current Vulvovaginal Atrophy (VVA) Treatment by means of a questionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Secondary Outcome Measures
NameTimeMethod
Reasons for not Following HCP Instructions for Treatment of VVADay 0
Symptoms that Most Benefit from VVA Treatment According to the PatientDay 0
Time to Improvement in VVA Symptoms According to the PatientDay 0
Effect of Educational Level, Marital Status, Age, and Geographic Location on Treatment Adherence for VVADay 0
Factors that the Patient Identifies as Disadvantages of VVA Treatment by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Factors the HCP Identifies as Advantages of VVA Treatment by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the HCP's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

HCP´s Perception about Patient Non-compliance to Each of the VVA TreatmentsDay 0
Patients' Preferred Treatment, Route of Administration and Treatment Schedule According to the HCPDay 0
Other Factors that Influence Adherence According to the HCP Determined by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the HCP's selection of answers to questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Factors that According to the HCP and the Patient Influence the Patient's Decision to Discontinue TreatmentDay 0
Factors Positively Affecting the Patient's Adherence to Each Treatment According to the HCP and PatientDay 0
VVA Acknowledgement by the PatientDay 0
Other Factors that Affect Adherence to VVA Treatment in the Patient´s Opinion as Determined by a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Treatment Most Rejected by Patients According to the Opinion of the Healthcare Professional (HCP)Day 0
VVA Symptoms Acknowledged by the PatientDay 0
Importance Patient Gives to Follow the Instructions of her Doctor About the Treatment for VVADay 0
Factors that the Patient Identifies as Advantages of VVA Treatment by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Factors the HCP Identifies as Disadvantages of VVA Treatment by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the HCP's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Treatment Duration for Each Type of VVA Treatment According to the HCP and the PatientDay 0
Satisfaction with Current VVA Treatment by means of a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Acknowledgement of the Advantages and Disadvantages of Treatment for VVADay 0
Patient's Level of Compliance to the Treatment Scheme Prescribed by the HCP by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Importance Given by the Patient to Comply with the Treatment for VVADay 0
Preferred Route of Administration and Treatment Schedule for VVA Determined by a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Preferred Route of Administration and Treatment Schedule in the Opinion of the HCPDay 0
HCP's Perception of Treatment Duration for Each Type of VVA TreatmentDay 0
Patient Compliance with HCP instructions Regarding the Treatment Dosage by Means of a QuestionnaireDay 0

The results will be determined by an evaluation the patient's selection of answers to 32 questions designed to determine the patient's use of, compliance with, and satisfaction with treatments for vulvovaginal atrophy. The questions have answers on a 5-point scale with the lowest score for dissatisfaction and the highest score for satisfaction

Cervantes Quality of Life (QOL) Questionnaire Total Score and Domain ScoresDay 0

Trial Locations

Locations (3)

Clínica Teknon

🇪🇸

Barcelona, Spain

Hospital Universitario de Guadalajara

🇪🇸

Guadalajara, Spain

Instituto Palacios

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath